MedPath

Kinesiophobia in Prostate Cancer

Not Applicable
Completed
Conditions
Prostate Cancer
Kinesiophobia
Physical Inactivity
Interventions
Other: survey evaluation
Registration Number
NCT06131853
Lead Sponsor
Selcuk University
Brief Summary

This study aimed to investigate the effects of prostate cancer on patients' physical activity, kinesiophobia, fatigue and functionality.

This research is a prospective study to be conducted on volunteer individuals between the ages of 40-75. People diagnosed with prostate cancer (study group) and healthy adults who have not been diagnosed with prostate cancer before (control group) will be included in the study. The demographic characteristics, physical activity levels and quality of life of all individuals participating in the study will be evaluated with an online form. In demographic data, physical, sociodemographic data such as age (years), height (cm), body weight (kg), body mass index (kg/m2) and disease-specific information will be recorded. Physical activity level will be measured with the International Physical Activity Survey short form (UFAA), fatigue with the Functional Evaluation of Chronic Disease Treatment-Fatigue Questionnaire, fear of movement with the Causes of Fear of Movement Questionnaire, and quality of life with the Functional Evaluation of Cancer Treatment-Prostate Version questionnaire (KHTFD-Y).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • (for prostate cancer-study group)

    • Being between the ages of 40-75
    • Want to participate in the study
    • Being able to read and write
    • Being diagnosed with prostate cancer by a specialist physician,
    • Being able to provide their mobility independently,
  • (for healthy controls - control group)

    • Being between the ages of 40-75
    • Not having any previous cancer history and not having undergone cancer surgery
    • Volunteering to participate in the study
Exclusion Criteria
  • Those with a previously known or accompanying diagnosis of dementia
  • Not wanting to participate in the study
  • The individual has a disease that may prevent him or her from understanding and completing the survey.
  • Illiterates
  • Those who do not want to participate in the research voluntarily
  • Having active metastasis
  • Having undergone chemotherapy and radiotherapy in the last 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
control groupsurvey evaluation-
prostate groupsurvey evaluation-
Primary Outcome Measures
NameTimeMethod
International Physical Activity Survey short form10 minutes

The short form consists of 7 questions. The form provides information about the frequency and time spent in walking, moderate physical activity, and vigorous physical activity.

Functional Assessment of Fatigue Chronic Disease Treatment-Fatigue Questionnaire10 minutes

It consists of 13 questions that evaluate the level of fatigue that occurred during daily activities in the last 7 days. Scoring varies between 0-52. High scores indicate less fatigue.

Functional Evaluation of Cancer Treatment-Prostate Version questionnaire10 minutes

It consists of 13 questions that evaluate the level of fatigue that occurred during daily activities in the last 7 days. Scoring varies between 0-52. High scores indicate less fatigue.

Reasons for Fear of Movement Questionnaire10 minutes

It allows the causes of kinesiophobia to be identified and both biological and psychological causes to be determined separately. The average of the scores obtained from the biological and physiological subscales gives the total score from the survey. A 5-point Likert scoring (1 = Totally disagree, 5 = Completely agree) is used in the scale. An individual's high score from the survey indicates that he/she has more fear of movement.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Selcuk University

🇹🇷

Konya, Selcuklu, Turkey

© Copyright 2025. All Rights Reserved by MedPath